Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Brian Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Barbara Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.


SCHEDULE 13G



 
Brian Pratt
 
Signature:/s/ Brian Pratt
Name/Title:Brian Pratt
Date:04/21/2026
 
Barbara Pratt
 
Signature:/s/ Barbara Pratt
Name/Title:Barbara Pratt
Date:04/21/2026
Exhibit Information

Joint Filing Agreement, dated as of April 21, 2026, by and between the Reporting Persons, attached hereto.